Targets › GABRA3
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 4; Psychiatry, Gastroenterology; next expected readout Apr 2027.
Alpha subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain. GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (By similarity). (UniProt, P34903)
Open in Phaseline: the race on GABRA3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Xi'an Aerospace General Hospital | Ciprofol GABA-A receptor positive allosteric modulator | GABRA1, GABRA2, GABRA3 | Phase 4 | Cholelithiasis | – |
| University of California, Los Angeles | Intravenous Alcohol (6% ethanol v/v in saline) GABA-A receptor positive allosteric modulator; CNS depressant | GABRA1, GABRA2, GABRA3 | Phase 2 | Alcohol Use Disorder | Apr 2027 |
Alcohol Use Disorder (1) Cholelithiasis (1)
small molecule (2)
University of California, Los Angeles (1) Xi'an Aerospace General Hospital (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.